Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination w...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Zelenetz, Andrew D., Salles, Gilles, Mason, Kylie D., Casulo, Carla, Le Gouill, Steven, Sehn, Laurie H., Tilly, Herve, Cartron, Guillaume, Chamuleau, Martine E. D., Goy, Andre, Tam, Constantine S., Lugtenburg, Pieternella J., Petrich, Adam M., Sinha, Arijit, Samineni, Divya, Herter, Sylvia, Ingalla, Ellen, Szafer-Glusman, Edith, Klein, Christian, Sampath, Deepak, Kornacker, Martin, Mobasher, Mehrdad, Morschhauser, Franck
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2019
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497517/
https://ncbi.nlm.nih.gov/pubmed/30850381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-11-880526
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍